Financial Express, Delhi
Sat, 14 May 2016, Page 1

Responding to concerns expressed by developed countries like the US on Section 3(d) and compulsory licensing, Jaitely said: “We do believe that the balancing act which India has struck is responsible for life-saving drugs available at a reasonable cost in India compared to the rest of the world. So, our model seems to be both legal, equitable and WTO-compliant.”

Section 3(d) prevents evergreening of drug patents. Apart from novelty and inventive step, the section provides for improvement in therapeutic efficacy, a necessary condition for grant of patents when it comes to incremental inventions. Compulsory licensing allows domestic players to produce cheaper versions of patented drugs. The US and the EU have been pushing India to make appropriate changes to these provisions to boost innovation, R&D and foreign investment. Recently, releasing its annual SOI report, the US retained India on its priority watch list, citing “lack of sufficient measurable improvements” to the IP framework despite robust engagement and positive steps on intellectual property protection and enforcement by the Indian government in the last two years.

The finance minister said by 2017, trademarks can be registered within a month. Currently, in some cases, this process takes even a few years. According to Jaitely, there are seven objectives that guided the policy mechanism, which include IPR-public awareness, stimulation of generation of IPRs, need for strong and effective laws and strengthening enforcement and adjudicatory mechanisms to combat infringements.

Hailing the move, industry body Nasscom said the new policy has captured issues, including difficulties that companies face in monetising intangibles like IPR, and the proposal to create a “simple loan guarantee scheme to encourage start-ups” based on IPRs as mortgageable assets, financial support and securitisation of IPRs for commercialisation by enabling valuation of IPR assets through arrangements.

Announcing the approval to the policy by the Cabinet, finance minister Arun Jaitley stressed that India’s IPR policies are WTO-compliant. He added that one must encourage invention of life-saving drugs and at the same time “we must also be conscious of the need to make it available at a reasonable cost so that drug cost does not become prohibitive as it has become in some parts of the world.”